ID93+GLA-SE
PreclinicalBiologic
ID93+GLA-SE is one of 14 biologic programs targeting Vaccination. It is currently in Preclinical.
1
Indications
3
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Vaccination
#DrugCompanyPhaseTrials
1Hepatitis B Vaccine
SanofiPhase 3
Rotarix ™
GSKPhase 3
Measles Vaccine
GSKPhase 3
Havrix
GSKPhase 3
PCV21
SanofiPhase 3
Rotateq
Merck & Co.Phase 3
Priorix
GSKPhase 3
M-M-R II Vaccine
SanofiPhase 3
Vaxelis Vaccine
SanofiPhase 3
Varivax
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ID93+GLA-SE. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- QQuratis Inc.